<DOC>
	<DOCNO>NCT02812394</DOCNO>
	<brief_summary>This study open-label , randomize , three-period cross-over pharmacokinetic evaluation CVT-301 compare Reference Listed Drug ( RLD ) , orally administer carbidopa/levodopa , healthy volunteer .</brief_summary>
	<brief_title>A Study Compare Two Dose Strengths CVT-301 ( Levodopa Inhalation Powder ) With Oral Dose SinemetÂ® ( Carbidopa-levodopa ) Tablets</brief_title>
	<detailed_description>The primary objective determine relative bioavailability two CVT-301 ( dose level 1 2 ) capsule compare Reference Listed Drug ( RLD ) per milligram basis .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>In good general health determine medical history , physical examination , electrocardiogram ( ECG ) , vital sign , clinical laboratory evaluation ; FEV1/FVC 5th percentile predict normal distribution age gender ; Body Mass Index ( BMI ) 18 30 kg/m2 No flulike syndrome respiratory infection within 2 week prior Screening Visit ; Negative drug alcohol testing ; Negative pregnancy test female subject</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Episodic motor fluctuation ( OFF period )</keyword>
</DOC>